A Review of the Efficacy of FDA-Approved <i>B. anthracis</i> Anti-Toxin Agents When Combined with Antibiotic or Hemodynamic Support in Infection- or Toxin-Challenged Preclinical Models.

Whether administered at 0, 6 or 9 h, AIG increased survival and overall had a highly significant survival effect ( p = 0.006) ( Figure 6 ).

also in 132,142 other papers

As with Raxibacumab, AIG reduced norepinephrine requirements, increased the SI and urine output, decreased net fluid balance and creatinine, increased LVEF and ABE and decreased AaO 2 , ALT and AST significantly or in trends approaching significance ( p ≤ 0.1) ( Figure 6 , Figure 7 and Figure 8 ). 4.

also in 2,640 other papers